GPCR

Structure Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality4/10
  • Growth↓ 1/10
  • Value↑ 6/10
Structure Therapeutics sales and earnings growth
GPCR Growth
Low
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -2.56%
  • FCF Y/Y↓ -91.49%
Structure Therapeutics gross and profit margin trends
GPCR Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ 0.00%
Structure Therapeutics net debt vs free cash flow
GPCR Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Structure Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗